19 March 2021 (Friday) - ASH Update

The ASH sent their spotlight on chronic leukaemias today. Perhaps all a bit too clinical for me, but all useful stuff:

Durable Efficacy With LOXO-305 in Heavily Pretreated CLL/SLL
LOXO-305 was associated with promising response and efficacy rates in patients with poor-prognosis chronic lymphocytic leukemia/small lymphocytic lymphoma, according to findings presented at the 2020 ASH Annual Meeting.
Asciminib Receives Breakthrough Therapy Designation for CML
The FDA’s decision is based on data from the phase III ASCEMBL trial evaluating asciminib for the treatment of patients with Ph+ CML in chronic phase, including those who harbor the T315I mutation.
Guest Commentary: The Future of Chronic Graft-Versus-Host Disease
Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and challenges in the management of chronic graft-versus-host disease – the subject of a recent National Institutes of Health Consensus Conference.

No comments:

Post a Comment